Jazz Pharmaceuticals Signs Exclusive Licensing Deal with Saniona for SAN2355 Development

Jazz Pharmaceuticals plc and Saniona have entered into a global licensing agreement granting Jazz exclusive worldwide rights to develop and commercialize SAN2355, a subtype-selective Kv7.2/Kv7.3 activator currently in preclinical development. SAN2355 is designed to address epilepsy and other neurological conditions by overcoming the limitations of existing non-selective Kv7-targeting compounds.

Under the agreement, Jazz will lead and fund the clinical development, regulatory filings, and global commercialization efforts for SAN2355.

Thomas Feldthus, CEO of Saniona, highlighted the partnership’s strategic value: “Our collaboration with Jazz leverages their leadership in epilepsy and their strong track record in advancing clinical programs and commercializing innovative neuroscience therapies. This allows Saniona to focus on progressing other pipeline assets while expanding treatment options for patients with neurological and psychiatric disorders.”

Robert Iannone, M.D., executive vice president and chief medical officer at Jazz Pharmaceuticals, expressed optimism about the asset’s potential. “SAN2355 is a unique and highly promising preclinical asset that could become a best-in-class Kv7 activator for epilepsy treatment. This agreement strengthens our early-stage neuroscience portfolio and underscores our commitment to developing novel therapies for epilepsy and related neurological conditions.”

The deal marks a significant step for Jazz in expanding its neuroscience pipeline and enhancing therapeutic options for patients with serious neurological diseases.